Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from BioAge Labs, Inc. ( (BIOA) ).
BioAge Labs reported its full-year 2025 results and late-2025 operational milestones on March 24, 2026, highlighting strong progress for BGE-102, its oral, brain-penetrant NLRP3 inhibitor. Positive interim Phase 1 data in December 2025 and January 2026 showed robust reductions in inflammatory biomarkers of cardiovascular risk in healthy volunteers and participants with obesity, and the company expanded development to include cardiovascular and ophthalmology indications.
The company plans to initiate a Phase 2a cardiovascular risk trial for BGE-102 in the first half of 2026 and a Phase 1b/2a study in diabetic macular edema in mid-2026, while also advancing an APJ agonist program toward an IND filing by the end of 2026. Financially, BioAge increased collaboration revenue to $9 million in 2025, widened its net loss to $80.6 million on higher R&D and G&A spending, completed a $132.3 million upsized follow-on equity offering in early 2026, and ended 2025 with $285.1 million in cash and securities, which it expects will fund operations through 2029.
BioAge also reported progress in multi-year collaborations with Novartis and Lilly focused on aging-related targets, and continued large-scale molecular profiling of HUNT Biobank samples to feed its discovery engine. The combination of advancing clinical programs, expanded indications, strengthened balance sheet and strategic partnerships underscores BioAge’s push to establish a differentiated position in aging-focused metabolic and inflammatory disease therapeutics.
The most recent analyst rating on (BIOA) stock is a Buy with a $52.00 price target. To see the full list of analyst forecasts on BioAge Labs, Inc. stock, see the BIOA Stock Forecast page.
Spark’s Take on BIOA Stock
According to Spark, TipRanks’ AI Analyst, BIOA is a Neutral.
The score is held back primarily by weak fundamentals—large losses and substantial cash burn—despite a low-leverage balance sheet. Technicals are a clear positive with strong trend and momentum. Corporate updates are supportive (positive clinical data and added funding runway), while valuation remains unattractive due to ongoing losses and no dividend.
To see Spark’s full report on BIOA stock, click here.
More about BioAge Labs, Inc.
BioAge Labs, Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. Its lead candidate, BGE-102, is an orally available, brain-penetrant small-molecule NLRP3 inhibitor being developed for cardiovascular risk and retinal diseases, supported by a data-driven discovery platform and strategic pharma collaborations.
The company leverages partnerships with large pharmaceutical firms and extensive longitudinal biobank data to identify novel aging-related targets. BioAge is advancing both small molecules like BGE-102 and APJ agonist programs, positioning itself in the competitive cardiometabolic and ocular disease markets with a pipeline aimed at multiple inflammasome- and metabolism-driven indications.
Average Trading Volume: 729,059
Technical Sentiment Signal: Strong Buy
Current Market Cap: $777.8M
Find detailed analytics on BIOA stock on TipRanks’ Stock Analysis page.